Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes: Lessons from the FIGARO-DKD trial
Haller, Hermann
Herz, 2022-10, Vol.47 (5), p.401-409
[Periódico revisado por pares]
Heidelberg: Springer Medizin
Texto completo disponível